These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31939146)

  • 21. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Cottin V; Spagnolo P; Bonniaud P; Dalon F; Nolin M; Kirchgässler KU; Van Ganse E; Belhassen M
    Respir Med Res; 2023 Jun; 83():100951. PubMed ID: 36434913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease stage-related survival in idiopathic pulmonary fibrosis patients treated with nintedanib and pirfenidone: An exploratory study.
    Bocchino M; Bruzzese D; Scioscia G; Capitelli L; Tondo P; Rea G; Barbaro MPF; Lacedonia D
    Respir Med Res; 2023 Nov; 84():101013. PubMed ID: 37302161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.
    Loveman E; Copley VR; Colquitt JL; Scott DA; Clegg AJ; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
    BMC Pharmacol Toxicol; 2014 Nov; 15():63. PubMed ID: 25410822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe.
    Kaushal M; Talwar D; Prajapat D; Kumar S; Acharya S; Talwar D
    Cureus; 2022 Feb; 14(2):e22606. PubMed ID: 35371648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
    Inomata M; Nishioka Y; Azuma A
    Core Evid; 2015; 10():89-98. PubMed ID: 26346347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
    Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
    BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study.
    Vianello A; Salton F; Molena B; Turato C; Graziani ML; Braccioni F; Frassani V; Sella D; Pretto P; Paladini L; Sukthi A; Confalonieri M
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32033147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone.
    Ipatova AY; Koerner PH; Miller RT; Staskon F; Radi M
    Clin Med Insights Circ Respir Pulm Med; 2019; 13():1179548419834922. PubMed ID: 30890862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience.
    Levra S; Guida G; Sprio AE; Crosa F; Ghio PC; Bertolini F; Carriero V; Albera C; Ricciardolo FLM
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).
    Saito S; Alkhatib A; Kolls JK; Kondoh Y; Lasky JA
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1740-S1754. PubMed ID: 31632751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis.
    Roach KM; Castells E; Dixon K; Mason S; Elliott G; Marshall H; Poblocka MA; Macip S; Richardson M; Khalfaoui L; Bradding P
    Front Pharmacol; 2021; 12():679388. PubMed ID: 34712131
    [No Abstract]   [Full Text] [Related]  

  • 37. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs.
    Audibert C; Livoti C; Caze A
    Contemp Clin Trials Commun; 2016 Aug; 3():80-85. PubMed ID: 29736460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia.
    Khan MA; Ghamdi BA; Alhamadi M; Rajendram R; Alyami S; Al-Gamedi M; Al-Harbi A; Al-Jahdali H
    Ann Thorac Med; 2023; 18(2):79-85. PubMed ID: 37323372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
    Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
    Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.